Hereditary Transthyretin Amyloidosis Polyneuropathy

Area of Science:

• Neurology
• Cardiology
• Genetics
• Medical Imaging

Background:

• Hereditary transthyretin amyloidosis (ATTRv) is a progressive disease impacting multiple organs.
• Recent years have seen substantial progress in ATTRv diagnosis, management, and patient monitoring.
• Traditional diagnostic methods like biopsies are increasingly supplemented by advanced imaging.

Purpose of the Study:

• To review current knowledge on ATTRv polyneuropathy and its management.
• To discuss strategies for enhancing early diagnosis and monitoring of ATTRv.
• To explore emerging trends and future directions in ATTRv research and therapy.

Main Methods:

• Review of recent advancements in ATTRv diagnosis, including imaging techniques like ^99mTc-PYP scans.
• Analysis of current and emerging therapeutic strategies, such as antisense oligonucleotides and RNA interference.
• Discussion of challenges in ATTRv management, including early detection, mixed phenotypes, and novel complications.

Main Results:

• Significant improvements in quality of life and survival for ATTRv patients due to novel treatments.
• ^99mTc-PYP scans are becoming a preferred alternative to biopsies for disease confirmation.
• Emerging therapies like CRISPR and amyloid antibodies show future potential.

Conclusions:

• Despite progress, challenges in early ATTRv diagnosis and management persist.
• Future research focuses on preventive therapies, improved biomarkers, and targeted treatments for resistant organs.
• Integration of novel imaging and artificial intelligence promises enhanced diagnostic capabilities for ATTRv.